Literature DB >> 25234769

[Gastroenteropancreatic endocrine tumors].

C Schmid-Tannwald1, C M Schmid-Tannwald, M F Reiser, F Berger.   

Abstract

CLINICAL/METHODICAL ISSUE: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are a rare, heterogeneous group of neoplasms. Only 2% of gastrointestinal tumors belong to the group of neuroendocrine neoplasms. STANDARD RADIOLOGICAL
METHODS: A wide spectrum of diagnostic imaging modalities is available: apart from ultrasound not only computed tomography (CT) but also magnetic resonance imaging (MRI) and positron emission tomography CT (PET-CT) play an important role in detection and staging of GEP-NETs. METHODICAL INNOVATIONS: The PET-CT technique with somatostatin analogues is used for staging as well as for evaluation and monitoring of treatment with peptide radionuclide radiation therapy. PERFORMANCE: According to the literature NETs of the small bowel with a size over 3 cm can be detected with a sensitivity of 84.7% and a specificity of 96.6% using CT enteroclysis and MR enteroclysis provides the detection of NETs of the small bowel in 93.3% of cases. 'The sensitivity of MRI in detection of pancreatic NETs is between 74% and 100% and is, therefore, higher than CT. Detection of small primary tumors is carried out using PET-CT and seems to be the most sensitive imaging modality to identify the exact location. On the other hand MRI has to be regarded as the best imaging modality for detection of liver metastases compared to CT and PET-CT. ACHIEVEMENTS: The role of diagnostic imaging is to identify the exact location of the primary tumor and possible metastases, to define an appropriate therapy and to monitor treatment effects; however, the choice of the most appropriate diagnostic imaging modality varies depending on the location and type of the primary tumor. PRACTICAL RECOMMENDATIONS: The GEP-NETs are predominantly well-vascularized; therefore, dual-phase CT/MR imaging with the arterial and venous phases after contrast media injection is mandatory for detection and localization of primary tumors and metastases. For whole body staging CT and PET-CT should be performed.

Entities:  

Mesh:

Year:  2014        PMID: 25234769     DOI: 10.1007/s00117-014-2689-4

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  26 in total

1.  Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection.

Authors:  T Ichikawa; M S Peterson; M P Federle; R L Baron; H Haradome; Y Kawamori; S Nawano; T Araki
Journal:  Radiology       Date:  2000-07       Impact factor: 11.105

Review 2.  [Imaging of neuroendocrine tumors of the pancreas].

Authors:  C Vick; C J Zech; S Höpfner; T Waggershauser; M Reiser
Journal:  Radiologe       Date:  2003-04       Impact factor: 0.635

Review 3.  Carcinoid tumors of the small bowel: a multitechnique imaging approach.

Authors:  Karen M Horton; Ihab Kamel; Lawrence Hofmann; Elliot K Fishman
Journal:  AJR Am J Roentgenol       Date:  2004-03       Impact factor: 3.959

4.  [Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT].

Authors:  A R Haug; G Assmann; C Rist; R Tiling; G P Schmidt; P Bartenstein; M Hacker
Journal:  Radiologe       Date:  2010-04       Impact factor: 0.635

5.  Possible small-bowel neoplasms: contrast-enhanced and water-enhanced multidetector CT enteroclysis.

Authors:  Frank Pilleul; Marianne Penigaud; Laurent Milot; Jean-Christophe Saurin; Jean-Alain Chayvialle; Pierre-Jean Valette
Journal:  Radiology       Date:  2006-10-19       Impact factor: 11.105

6.  Diffusion-weighted MRI of metastatic liver lesions: is there a difference between hypervascular and hypovascular metastases?

Authors:  Christine Schmid-Tannwald; Stephen Thomas; Marko K Ivancevic; Farid Dahi; Carsten Rist; Ila Sethi; Aytekin Oto
Journal:  Acta Radiol       Date:  2013-08-28       Impact factor: 1.990

Review 7.  MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA.

Authors:  Christoph J Zech; Karin A Herrmann; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Magn Reson Med Sci       Date:  2007       Impact factor: 2.471

Review 8.  The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.

Authors:  Günter Klöppel; Aurel Perren; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

Review 9.  State-of-the-art magnetic resonance imaging of pancreatic cancer.

Authors:  Wolfgang Schima; Ahmed Ba-Ssalamah; Peter Goetzinger; Martina Scharitzer; Claus Koelblinger
Journal:  Top Magn Reson Imaging       Date:  2007-12

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.